Clinical Trial Update: Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations [Phase 2]

View source ↗

Summary

Phase 2 study of PF-06649751 in Parkinson's disease patients with motor fluctuations has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease with Motor Fluctuations

Drugs mentioned

• PF-06649751 (PF-06649751)

Snippet

Sponsor: Pfizer | Conditions: Parkinson's Disease With Motor Fluctuations | Phase 2 | Status: TERMINATED | Results posted: 2019-04-12